Detalhe da pesquisa
1.
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
Mar Drugs
; 22(4)2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38667795
2.
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Invest New Drugs
; 41(5): 677-687, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556023
3.
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Invest New Drugs
; 40(1): 91-98, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453241
4.
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Invest New Drugs
; 39(5): 1275-1283, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704620
5.
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gynecol Oncol
; 163(2): 237-245, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521554
6.
Lurbinectedin in the treatment of relapsed small cell lung cancer.
Future Oncol
; 17(18): 2279-2289, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33736462
7.
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Int J Gynecol Cancer
; 31(11): 1428-1436, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34610971
8.
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Lancet Oncol
; 21(5): 645-654, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32224306
9.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(9): 829-838, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28586279
10.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol
; 17(2): 234-242, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26708155
11.
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Future Oncol
; 11(3): 421-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25675123
12.
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Lung Cancer
; 188: 107448, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38198859
13.
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.
Pharmaceuticals (Basel)
; 17(2)2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38399397
14.
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
Front Oncol
; 13: 1152371, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37397388
15.
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Eur J Cancer
; 192: 113259, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37634282
16.
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Cancer Med
; 12(4): 3999-4009, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36127823
17.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Lancet Respir Med
; 11(1): 74-86, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36252599
18.
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.
Cancer Chemother Pharmacol
; 90(4): 285-299, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029310
19.
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Eur J Cancer
; 172: 340-348, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830841
20.
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Clin Cancer Res
; 28(13): 2762-2770, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35486638